Naltrexin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naltrexin

Quick Facts

Property Description
Active Ingredient Naltrexone Hydrochloride
Form Oral tablet, Extended-release injection
Pharmacological Class Opioid Antagonist
General Purpose Support to reduce cravings and block euphoric effects
Origin Synthetic compound

What Type of Medicine is Naltrexin?

Naltrexin is a synthetic prescription medication classified as a pure opioid antagonist or opioid blocker. The active ingredient is Naltrexone Hydrochloride, a compound chemically related to oxymorphone but specifically engineered to be a non-addictive substance. It is designed without the ability to activate the central nervous system's opioid receptors, meaning it has no inherent euphoric or dependence-forming properties itself. Naltrexone serves as a foundational component in medication-assisted treatment for dependency, which underscores its established medical role.

Naltrexin Forms and General Purpose

The medication is available in two main drug forms: an oral tablet and an extended-release intramuscular injectable suspension. These different preparations offer flexibility in supporting long-term adherence to a recovery program. Unlike its related acute-use counterpart, Naloxone, Naltrexin is intended for sustained, long-term therapeutic use in adult patients. As an opioid antagonist, Naltrexin's primary purpose is to provide pharmacological assistance by physically occupying the opioid receptors in the brain, thereby neutralizing the intense feelings of reward and euphoria that are associated with the ingestion of external opioids or alcohol. The drug's blocking action is intended to diminish the urges and cravings associated with dependence. The medicine thus provides continuous support by removing the physical reward and dampening the neurological drive to use the substance, serving as a non-addictive adjunct to a comprehensive recovery plan.

Regulatory References

  1. NIH/NIDA: Medications for Opioid Use Disorder

What side effects are possible with Naltrexin?

Possible Side Effects and Safety Information

The safety profile for Naltrexin (Naltrexone Hydrochloride) is structured around officially documented adverse reactions and strict regulatory limitations. Side effects are classified by frequency, based on clinical trial data, and grouped by the physiological system affected.

Frequency Classification Examples of Documented Effects
Very Common Nausea, headache, anxiety, insomnia
Common Vomiting, diarrhea, abdominal pain, dizziness, rash, joint pain, elevated liver enzymes

Adverse effects are documented across several body systems, including Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders. The most frequently reported reactions, such as nausea and headache, are typically observed with greater frequency at the initiation of treatment.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights several clinically significant safety concerns. The medicine is strictly contraindicated in any individual currently receiving opioid analgesics, those dependent on opioids, or those in a state of acute opioid withdrawal, as administration can precipitate a severe withdrawal syndrome. A key safety constraint is the potential for hepatotoxicity (liver injury); Naltrexin is contraindicated in patients with acute hepatitis or liver failure. Furthermore, the label notes that patients must be observed for the development of depression or suicidal thinking and behavior. Caution is also advised when administering the medicine to patients with moderate to severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents provide specific information regarding overexposure to Naltrexin. Clinical experience with acute overdose is limited, and studies utilizing high doses (up to 800 mg per day) showed a notable absence of specific symptoms or clinical signs of toxicity. Non-specific manifestations such as nausea and vomiting have been reported in this context. The primary risk regarding high-dose exposure is the potential for dose-related hepatocellular injury (liver damage).

Officially Documented Risks and Emergency Actions

Due to the potential for organ toxicity and the lack of distinct acute symptoms, official guidance mandates immediate action in the event of suspected overexposure. Patients with pre-existing hepatic impairment require special consideration during management.

Category Regulatory Statement
Immediate Action Required Seek immediate medical attention for any suspected overdose.
Antidote Status No specific antidote is known.

Management is restricted to symptomatic and supportive treatment, including continuous monitoring. Observation protocols require intensive assessment of vital signs and checks for potential liver injury.

Therapeutic Uses of Naltrexin

What Naltrexin Treats: Main Uses and Benefits

Naltrexin is commonly used within Medication-Assisted Treatment (MAT) programs to provide supportive therapeutic relief in situations involving distressing symptoms related to dependence. The medication is commonly used to support recovery from Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD), addressing symptom patterns associated with chronic substance dependence.

A core therapeutic benefit of Naltrexin is its ability to address symptoms of intense cravings that create noticeable physiological strain. It is also relevant for easing the symptoms associated with the risk of returning to substance use. By addressing the symptom clusters that may become intense or disruptive and easing the powerful urges for both alcohol and opioids, the medication provides support that helps ease the overall symptom burden associated with these difficult manifestations. This assistance is applied in clinical settings that involve acute or unstable symptom patterns following detoxification.

“This critical assistance assists with maintaining functional stability during recovery and helps improve day-to-day comfort during symptomatic periods.”


Quick Fact: Symptomatic Support Focus

Category Description
Primary Indication Alcohol Use Disorder and Opioid Use Disorder
Main Symptom Target Intense substance cravings and powerful urges
Therapeutic Benefit Relevant for maintaining stable sobriety and addressing heavy drinking episodes

Eligibility and Restrictions for Use

The eligibility for Naltrexin use is strictly defined by regulatory bodies and centers on the patient's current clinical and physiological status.

Contraindicated Populations

Naltrexin is absolutely contraindicated for use in individuals who:

  • Are currently receiving opioid analgesics or any opioid-containing medication.
  • Have current physiologic opioid dependence or are in acute opioid withdrawal.
  • Have failed the naloxone challenge test or have a positive urine screen for opioids.
  • Have acute hepatitis or liver failure.
  • Have a known hypersensitivity to naltrexone or any component of the formulation.

Eligibility Constraints

Population Group Regulatory Status
Age (Children/Adolescents) Not recommended; safety and effectiveness are not established for those under 18 years old.
Age (Older Adults) Use for opiate dependence is not established; requires caution.
Hepatic/Renal Impairment Caution and monitoring are advised for patients with existing liver disease or renal impairment.
Pregnancy/Lactation Conditional use (e.g., FDA Category C in pregnancy); requires a risk-benefit assessment, and caution is advised regarding excretion into breast milk.

All eligible patients must be opioid-free following detoxification before initiating treatment, as verified by appropriate testing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Naltrexin is defined by its classification as a pure opioid antagonist, leading to specific regulatory prohibitions detailed in official documents.


Contraindicated and Restricted Combinations

Naltrexin is strictly contraindicated for co-administration with any opioid analgesic, including prescription pain relievers, and all opioid-containing medicines, such as certain cough or antidiarrheal remedies. This prohibition is mandatory because Naltrexin will competitively block the effects of the opioid, which carries the documented risk of precipitating a severe acute opioid withdrawal reaction.

Specific medicinal products that must not be combined with Naltrexin include Thioridazine (due to documented central nervous system effects) and Bremelanotide (due to decreased Naltrexin systemic exposure). The medication must also not be started until the patient has maintained an opioid-free interval of at least seven to ten days, a required timing-based constraint.


Metabolic and Population Considerations

Naltrexin's metabolism does not involve the CYP450 enzyme system, meaning most common enzyme-mediated drug-drug interactions are not predicted. However, caution is required in patients with renal or hepatic impairment because Naltrexin and its primary metabolite are excreted mainly by these organs. Reduced clearance in these populations can lead to increased drug accumulation. Official documentation notes no specific dangerous interaction between Naltrexin and alcohol.

Mechanism of Action

Naltrexin functions as a competitive opioid receptor antagonist, exhibiting high affinity for the mu (mu), kappa (kappa), and delta (delta) opioid receptors within the central and peripheral nervous systems. Following systemic absorption and distribution, the molecule preferentially occupies the orthosteric binding site on these G-protein coupled receptors.

Binding of Naltrexin to the mu-opioid receptor prevents the subsequent binding and activation by endogenous opioid peptides, such as beta-endorphin and enkephalins. This blockade maintains the mu-opioid receptor in an inactive conformation. Intracellularly, this inhibition prevents the mathrmGi/o protein from dissociating and inhibiting adenylate cyclase. Consequently, the downstream cyclic adenosine monophosphate (cAMP) signaling pathway remains unmodulated. The resulting system-level physiological consequence is the prevention of the characteristic mu-opioid receptor-mediated signal transduction cascade and its corresponding downstream effects on neuronal excitability and neurotransmitter release.

Dosage and Administration Information

Naltrexin, the generic name for naltrexone hydrochloride, is an opioid antagonist used as part of a comprehensive treatment program for Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). It is available as an oral tablet and an extended-release injection. Always follow the specific instructions and dosage provided by your healthcare professional.

Oral Tablet Administration

  • Dosage: The typical dose for AUD is 50 mg once daily. For OUD, treatment often begins with a 25 mg dose (half a tablet) and is increased to 50 mg daily if no withdrawal symptoms occur. Alternative dosing schedules may be used for AUD, such as 100 mg every other day, 150 mg every third day, or a three-times-weekly regimen.
  • Timing: The tablet is usually taken once a day. You may take it with or without food. Taking it with or immediately following a meal may help reduce the common side effect of nausea.
  • Compliance: Do not stop taking Naltrexin suddenly or alter your dose without consulting your physician. If you miss a dose, take it as soon as you remember, unless it is nearly time for your next scheduled dose, in which case you should skip the missed dose and resume your regular schedule. Do not take a double dose.

Important Pre-treatment Requirement

Do not start Naltrexin if you are currently using opioids (including prescribed, over-the-counter, or illicit drugs), or if you have an active physiological dependence on opioids. For oral naltrexone, you must be opioid-free for at least 7 to 10 days prior to initiation to prevent precipitating a severe and sudden opioid withdrawal syndrome. Your doctor may perform a urine screen or a naloxone challenge test before starting treatment for OUD.

Other Considerations

Naltrexin is generally contraindicated in cases of acute hepatitis or liver failure. Patients with liver or kidney impairment may require a lower dose. During treatment, you should carry identification indicating that you are taking Naltrexin.

Recent Clinical Evidence

Naltrexin: Recent Clinical Evidence

Clinical trials on Naltrexin have examined whether it can be associated with a change in the frequency and severity of migraine attacks. Furthermore, research has explored whether the combination of Naltrexin and standard-of-care was associated with temporary changes in symptom severity during acute migraine episodes. Studies have investigated the profile of Naltrexin for research participants who had not responded well to other therapies.


Overview of Research Objectives

The primary objective of the initial Phase 3 randomized controlled trials (RCTs) was to evaluate the potential of a specific amount of Naltrexin to affect the number of monthly migraine days. Secondary objectives included assessing impact on acute migraine-associated symptoms and measuring quality-of-life indicators.

Evaluation in Chronic Migraine

Key studies have evaluated whether participants who took Naltrexin under the conditions of the study experienced a significant reduction in monthly migraine days; research explored the potential impact on quality-of-life measures.

  • Dose-Finding: Research explored various quantities to determine the highest level of participant tolerability in the study regimen.
  • Response Rates: Analyses focused on the proportion of trial participants who reported a 50% reduction in migraine days per month.

Evaluation in Acute Migraine

Research has also explored the use of a specific, single amount of Naltrexin during the acute phase of a migraine episode.

  • Time to Change in Severity: Studies evaluated the time until participants reported a reduction in pain severity.
  • Rescue Medication Use: Researchers collected data on whether participants required "rescue" (secondary) medication within 24 hours of taking the study drug.

Safety Profile: Research Findings on Tolerability

The overall safety profile of Naltrexin was assessed throughout all clinical development phases.

  • Adverse Events: Reported side effects included temporary nausea and fatigue.
  • Exclusion Criteria: Trials excluded participants with uncontrolled hypertension.

Key Studies & References

  1. Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine (ANODYNE-1) (ClinicalTrials.gov Identifier: NCT03061734)

Frequently Asked Questions (FAQ)

Common questions about Naltrexin (FAQ)


Q: What is the difference between Naltrexin and similar medicines?

A: Official information describes Naltrexin as a pure opioid antagonist, which means it works by blocking the opioid receptors in the body. Other medicines used in treatment for substance use disorder may function as partial opioid agonists or full opioid agonists, which work differently by activating the receptors rather than blocking them.


Q: Why does Naltrexin need to be taken every day?

A: The purpose of Naltrexin is to maintain a continuous, consistent blocking effect at the opioid receptors. Official documents indicate that the duration of the opioid-blocking effect for the usual oral dose is approximately 24 hours, which is why administration is typically part of a daily regimen.


Q: Is Naltrexin addictive or habit-forming?

A: No, Naltrexin is not considered addictive. Regulatory labeling states that taking naltrexone hydrochloride is not associated with the development of tolerance or physical dependence.


Q: How quickly should I expect to notice any effects from Naltrexin?

A: The oral tablet is rapidly absorbed into the body. Studies show that peak levels of the drug and its primary active component generally occur in the bloodstream within one hour of taking a dose.


Q: Does Naltrexin affect how other pain medicines work?

A: Yes, Naltrexin will competitively block the pain relief effects of any opioid-based medicines. For most common non-opioid pain relievers, Naltrexin's metabolism does not typically involve the CYP450 enzyme system, meaning interactions of that specific nature are not generally predicted, but this should be clarified due to the regulatory requirements for pre-treatment screening.


Q: Is Naltrexin safe to use during pregnancy or while breastfeeding?

A: Official information classifies Naltrexin as Pregnancy Category C, meaning it should only be used if the potential benefit justifies the potential risk. Since the drug and its active components are known to be excreted into human milk, a healthcare professional determines whether to discontinue nursing or discontinue the drug.


Q: What are the most common reasons why a doctor might prescribe Naltrexin?

A: Naltrexin is officially approved by regulatory bodies exclusively for the treatment of Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). It is intended to be used as part of a comprehensive treatment program.


Q: Is Naltrexin a controlled substance?

A: No. Naltrexin is a prescription-only medicine but is not classified as a controlled substance under regulatory acts because it has no misuse or dependence potential.


Q: Can older adults use Naltrexin safely?

A: The safety and effectiveness of Naltrexin in the geriatric population have not been definitively established. Clinical studies on the pharmacokinetics (how the body handles the drug) of the Naltrexin extended-release injection have not been formally evaluated in this population.


Q: Are there different forms of Naltrexin available, like pills versus injections?

A: Yes, Naltrexin is available in two main forms. It can be administered as an oral tablet taken daily or as an extended-release injectable suspension that is administered once a month by a healthcare professional.


Q: Is there a risk of withdrawal symptoms if Naltrexin is stopped suddenly?

A: Official information indicates that stopping Naltrexin is not associated with the development of physical dependence or withdrawal symptoms caused by the Naltrexin medication itself.


Q: Can Naltrexin cause mood changes or depression?

A: The regulatory label highlights the potential for the development of depression or suicidal thinking and behavior, requiring patients to be observed for these changes during treatment. Anxiety and insomnia are also listed as very common side effects reported in clinical trials.


Q: Can Naltrexin cause weight loss or weight gain?

A: Weight gain or increased appetite are not listed among the most common adverse events in regulatory documents. However, frequent side effects such as nausea, vomiting, or loss of appetite, which typically occur at the start of treatment, may affect appetite or weight.


Q: Is Naltrexin used for conditions other than its primary approved uses?

A: Naltrexin is approved by regulatory bodies exclusively for the treatment of Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). These are the only two conditions specified in the official indications for use.


Q: What is the eligibility criteria for starting Naltrexin?

A: Regulatory criteria require that Naltrexin should not be started if a patient is receiving opioid pain medicines, is opioid-dependent, or is in acute opioid withdrawal. Patients are required to be opioid-free for a specific period before starting the oral tablet. It is also contraindicated in patients with acute hepatitis or liver failure.


Q: Is Naltrexin something I have to take forever, or is it temporary?

A: The required duration of Naltrexin treatment varies significantly. The length of treatment is determined by a healthcare professional based on the individual's progress and the severity of their condition, and is not defined as permanent or temporary for all patients.


Q: Does Naltrexin cause stomach issues or nausea?

A: Yes, gastrointestinal issues are common. Official documentation lists nausea as a very common side effect, while vomiting, diarrhea, and abdominal pain are classified as common side effects reported in clinical trials.


Q: Will taking Naltrexin impact my ability to drive or operate machinery?

A: Regulatory information suggests that individuals determine how Naltrexin affects them before driving or operating heavy machinery. The medicine can cause side effects like dizziness or somnolence (drowsiness) in some individuals.


Q: Are there different brand names for the medicine Naltrexin?

A: Yes, Naltrexin is the generic name for naltrexone hydrochloride. Approved brand names are available for both the oral tablet formulation and the extended-release injectable formulation (e.g., Vivitrol).


Q: What is the connection between Naltrexin and endorphins?

A: Naltrexin is an opioid antagonist that competitively binds to opioid receptors. By doing so, it blocks the effects of endogenous opioid peptides, which are naturally occurring substances in the body that include endorphins.


Q: Do children or teenagers ever take Naltrexin?

A: Safety and effectiveness have not been established in patients under the age of 18. Official guidance generally does not recommend it as a treatment option for anyone younger than 18 years of age.


Q: What kind of monitoring is required while taking Naltrexin?

A: Due to the potential for hepatotoxicity (liver injury), which is a key safety constraint, official information advises that blood tests to check liver function may be required before starting and periodically throughout Naltrexin treatment.


Q: Is the medicine Naltrexin difficult to get a prescription for?

A: Because Naltrexin is not classified as a controlled substance, it can generally be prescribed by any qualified healthcare provider who is licensed to prescribe medications, unlike some other treatments for substance use disorder.


Q: What is the history of Naltrexin and when was it approved?

A: The oral formulation of Naltrexin was first approved by the FDA decades ago. The extended-release injectable formulation was approved for Alcohol Dependence in 2006 and later for Opioid Dependence in 2010.


Q: Do patients typically feel a noticeable physical change when they start Naltrexin?

A: Some patients may feel noticeable physical changes at the beginning of treatment. Regulatory documents note that the most frequently reported side effects, such as nausea and headache, are typically observed with greater frequency during the initiation phase of therapy.


Q: Does Naltrexin have different uses at lower versus higher doses?

A: Naltrexin is approved for the same two conditions (AUD and OUD) regardless of the dose or formulation used. However, the exact daily milligram dosage or frequency of the regimen may differ depending on the specific condition being treated.


Q: How long does the effect of Naltrexin last in the body?

A: The active components of Naltrexin have different half-lives; the mean half-life of naltrexone is approximately 4 hours, and its active metabolite is approximately 13 hours. The resulting opioid-blocking effects of a 50 mg dose can last for about 24 hours.


Q: Are there any long-term health risks associated with taking Naltrexin?

A: The primary safety concern highlighted in regulatory documents is the potential for hepatotoxicity (liver injury), which is why the drug is contraindicated in liver failure. However, official information generally indicates that Naltrexin does not appear to be a hepatotoxin at the recommended doses.


Q: Can Naltrexin affect my sleep patterns?

A: Yes, official documentation lists insomnia (difficulty sleeping) as a very common side effect that was reported in clinical trials.


Q: How effective is Naltrexin based on clinical trial evidence?

A: Clinical trials for Naltrexin have explored that it may be associated with reductions in drinking days and heavy drinking days for patients with AUD compared to a placebo. For OUD, studies explored a reduction in the rate of relapse.

How should Naltrexin be stored and disposed of?

Storage and Disposal Instructions for Naltrexone

Official storage requirements vary by formulation to ensure product stability:

  • Oral Tablets: Must be stored at 25°C (77°F), allowing temperature excursions up to 30 C (86 F), in a tight container.
  • Extended-Release Injection: Requires refrigeration between 2 C to 8 C (36 F to 46 F) in its original carton to protect from light. The injection must not be frozen**.

All forms must be stored out of the sight and reach of children.

Official Disposal Procedures

Disposal instructions are formulation-specific. Unused tablets should be mixed with an unappealing substance (like cat litter) and sealed in a bag for disposal in household trash. All needles and syringes from the injectable kit must be placed immediately into a dedicated, puncture-resistant sharps disposal container and handled according to local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naltrexin found in:

A-Z Index: